PMID- 36233478
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221019
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 11
IP  - 19
DP  - 2022 Sep 23
TI  - Impact of Acid Suppression Therapy on Renal and Survival Outcomes in Patients 
      with Chronic Kidney Disease: A Taiwanese Nationwide Cohort Study.
LID - 10.3390/jcm11195612 [doi]
LID - 5612
AB  - Histamine-2-receptor antagonist (H2RA) has shown beneficial effects on the 
      kidney, heart, and sepsis in animal models and on the heart and COVID-19 
      infection in clinical studies. However, H2RAshave been used as a reference in 
      most epidemiological studies examining the association of proton pump inhibitors 
      (PPI) with outcomes. Therefore, we aimed to evaluate the effect of H2RA on renal 
      and survival outcomes in chronic kidney disease (CKD) patients. We used a 
      Taiwanese nationalhealth insurance database from 2001 to 2016 to screen 45,767 
      CKD patients for eligibility. We identified new users of PPI (n = 7121), H2RA (n 
      = 48,609), and users of neither PPI nor H2RA (as controls) (n = 47,072) during 
      follow-up, and finally created 1:1:1 propensityscore-matchedcohorts; each cohort 
      contained 4361 patients. Participants were followed up after 
      receivingacid-suppression agents or on the corresponding date until the 
      occurrence of end-stage renal disease (ESRD) in the presence of competing 
      mortality, death, or through the end of 2016. Compared toneither users, H2RAand 
      PPI users demonstrated adjusted hazard ratios of 0.40 (95% confidence interval, 
      0.30-0.53) for ESRDand 0.64 (0.57-0.72) for death and 1.15 (0.91-1.45) for ESRD 
      and 1.83 (1.65-2.03) for death, respectively. A dose-response relationship 
      betweenH2RA use with ESRD and overall, cardiovascular, and non-cardiovascular 
      mortality was detected. H2RA consistently provided renal and survival benefits on 
      multivariable stratified analyses and multiple sensitivity analyses. In 
      conclusion, dose-dependent H2RA use was associated with a reduced risk of ESRD 
      and overall mortality in CKD patients, whereas PPI use was associated with an 
      increased risk of overall mortality, not in a dose-dependent manner.
FAU - Chen, Yi-Chun
AU  - Chen YC
AUID- ORCID: 0000-0003-2153-272X
AD  - Division of Nephrology, Department of Internal Medicine, Dalin Tzu Chi Hospital, 
      Buddhist Tzu Chi Medical Foundation, Chiayi 622, Taiwan.
AD  - School of Medicine, Tzu Chi University, Hualien 970, Taiwan.
FAU - Chen, Yen-Chun
AU  - Chen YC
AUID- ORCID: 0000-0002-5089-2727
AD  - School of Medicine, Tzu Chi University, Hualien 970, Taiwan.
AD  - Division of Hepato-Gastroenterology, Department of Internal Medicine, Dalin Tzu 
      Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 622, Taiwan.
FAU - Chiou, Wen-Yen
AU  - Chiou WY
AUID- ORCID: 0000-0002-5541-6834
AD  - School of Medicine, Tzu Chi University, Hualien 970, Taiwan.
AD  - Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi 
      Medical Foundation, Chiayi 622, Taiwan.
FAU - Yu, Ben-Hui
AU  - Yu BH
AD  - Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi 
      Medical Foundation, Chiayi 622, Taiwan.
LA  - eng
GR  - DTCRD107(2)-E-02/Buddhist Dalin Tzu Chi Hospital/
PT  - Journal Article
DEP - 20220923
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC9570958
OTO - NOTNLM
OT  - CKD
OT  - ESRD
OT  - dose-response relationship
OT  - histamine-2-receptor antagonist
OT  - mortality
OT  - proton pump inhibitor
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/15 06:00
MHDA- 2022/10/15 06:01
PMCR- 2022/09/23
CRDT- 2022/10/14 02:15
PHST- 2022/08/02 00:00 [received]
PHST- 2022/09/11 00:00 [revised]
PHST- 2022/09/20 00:00 [accepted]
PHST- 2022/10/14 02:15 [entrez]
PHST- 2022/10/15 06:00 [pubmed]
PHST- 2022/10/15 06:01 [medline]
PHST- 2022/09/23 00:00 [pmc-release]
AID - jcm11195612 [pii]
AID - jcm-11-05612 [pii]
AID - 10.3390/jcm11195612 [doi]
PST - epublish
SO  - J Clin Med. 2022 Sep 23;11(19):5612. doi: 10.3390/jcm11195612.